NMR Metabolomics

From a single serum sample, we quantify multiple biomarkers — known and newly discovered. Precision Diagnostics.

AXINON® System

Now with FDA clearance, this is our core technology platform, incorporating diagnostic testing algorithms into nuclear magnetic resonance (NMR) spectroscopy. It's the first modular software-based system for clinical diagnostics.

Learn more

Precision Diagnostics

FDA-Cleared AXINON® System

Numares Health develops advanced biomarker tests to diagnose and measure disease progression for conditions related to metabolic dysfunction, such as chronic kidney, liver and cardiac diseases. 

We use nuclear magnetic resonance (NMR) spectroscopy to quantify multiple biomarkers — known and newly discovered — from a single serum sample. Machine learning then identifies the few, specific metabolites relevant to diagnosis.

The FDA-cleared AXINON® System is our core technology platform. It incorporates diagnostic testing algorithms into nuclear magnetic resonance (NMR) spectroscopy.

  • The FDA-cleared AXINON® LDL-p Test System, is a new tool physicians can use to measure lipoproteins for patients at risk for cardiovascular disease.

  • Currently, Numares is the only company in the US selling an FDA-cleared NMR test.

  • A second Numares assay is expected to gain FDA 510(k) clearance later this year, the AXINON® GFR(NMR) kidney function assay.

  • The AXINON®  HCC(NMR), a liver assessment and cancer early detection test, is in development. 

Personalized Risk Assessment. Multiplexed Metabolomics.


AXINON® LDL-p Test System: Now FDA-cleared, provides more detailed information about cardiac function than the standard LDL-C (low-density lipoprotein or “bad cholesterol”) measurement.

AXINON® lipoFIT®: For cardiovascular risk assessment. CE-marked in the EU. For research use only in the US.


AXINON® GFR(NMR): New kidney function assay that combines two novel biomarkers, valine and myo-inositol, with creatinine and cystatin C using highly accurate nuclear magnetic resonance (NMR) spectroscopy. FDA 510(k) pending and available as CE-labeled IVD in the EU.


AXINON® HCC(NMR): Liver risk assessment and cancer early detection test. In development.

Social Media

Numares Health and Mayo Clinic Strengthening Collaboration for Improved…


Kidney Week 2022

Join us Nov. 3-6 at exhibit booth #2533 during ASN Kidney…

Physicians who treat CDK patients: Join us in Orlando Thursday, Nov. 3,…


You did not activate the necessary cookies for this content.

activate necessary cookies and show content